Does cyclophosphamide still play a role in glomerular diseases?

Area of Science:

• Nephrology
• Pharmacology
• Oncology

Background:

• Cyclophosphamide is a prodrug metabolized into active agents, including phosphoramide mustard and acrolein.
• These metabolites exert cytotoxic and mutagenic effects by alkylating DNA, primarily in rapidly dividing cells.
• While repair mechanisms exist, high doses or prolonged use can overwhelm them, leading to significant toxicity.

Purpose of the Study:

• To review the mechanisms of action, adverse effects, and current clinical applications of cyclophosphamide in glomerular diseases.
• To highlight the importance of dose management and monitoring to mitigate risks associated with cyclophosphamide therapy.
• To assess the therapeutic utility of cyclophosphamide in specific nephropathies despite its potential toxicity.

Main Methods:

• Review of existing literature on cyclophosphamide's pharmacology and clinical use in nephrology.
• Analysis of adverse event profiles, including dose- and age-dependency.
• Evaluation of cyclophosphamide's efficacy and safety in conditions like minimal change disease, FSGS, membranous nephropathy, and lupus nephritis.

Main Results:

• Cyclophosphamide's active metabolite, phosphoramide mustard, causes DNA cross-links and breaks, leading to cell death.
• Key toxicities include bone marrow suppression, gonadal damage, and secondary malignancies; acrolein can cause hemorrhagic cystitis and bladder fibrosis.
• Despite risks, cyclophosphamide remains valuable as a steroid-sparing agent and in treating rapidly progressive glomerulonephritis and lupus nephritis, particularly when used cautiously.

Conclusions:

• Cyclophosphamide is an effective, cost-efficient treatment for select glomerular diseases, but its use necessitates strict precautions.
• Minimizing cumulative doses, avoiding long-term administration, and close clinical and hematological monitoring are crucial.
• Careful patient selection and management are paramount to balance the benefits of cyclophosphamide against its potential for severe adverse events in renal diseases.